The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study
详细信息 查看全文
- 作者：Daniel J. Lenihan ; MD1 ; daniel.lenihan@vanderbilt.edu" class="auth_mail" title="E-mail the corresponding author ; Patrick L. Stevens ; MD1 ; Mona Massey ; RN ; BSN2 ; Juan Carlos Plana ; MD3 ; Dejka M. Araujo ; MD4 ; Michelle A. Fanale ; MD5 ; Luis E. Fayad ; MD5 ; Michael J. Fisch ; MD ; MPH6 ; Edward T.H. Yeh ; MD2
- 关键词：Anthracycline cardiotoxicity ; biomarkers ; cardioprotection
- 刊名：Journal of Cardiac Failure
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：22
- 期：6
- 页码：433-438
- 全文大小：333 K
文摘
- •
Cardiac biomarkers, particularly BNP, can be part of an effective screening strategy for anthracycline-related cardiotoxicity.
- •
In this study, LVEF did not appear to be adequate for the detection of cardiotoxicity.
- •
BNP may allow us to direct cardioprotective therapy. More analysis with high-sensitivity troponin is needed.